

Table S1. Outcomes of Primary endpoints and Secondary endpoints from the treatment groups in PP population

Outcomes	Treatment		Risk Difference (95%CI)	Relative Risk (95%CI)	P value
	SAP	Regular CAS			
	n=26	n=30			
Primary endpoints	0 (0.0)	3 (10.0)	-10.0 (-22.5 to 1.1)	NA	0.24
Secondary endpoints					
HPP	0 (0.0)	7 (23.3)	-23.3 (-37.9 to -9.5)	NA	0.01
Procedure-related adverse events	1 (3.8)	2 (6.7)	-3.0 (-14.9 to 9.2)	0.79(0.34-1.83)	1.00
Myocardial infarction	1 (3.8)	1 (3.3)	-0.5 (-10.3 to 11.9)	1.07(0.26-4.39)	1.00
Hemorrhage 30 days to 1 year	0 (0.0)	0 (0.0)	NA	NA	1.00
Death at 30 days	0 (0.0)	0 (0.0)	NA	NA	1.00
Stroke resulting in deformity	0 (0.0)	0 (0.0)	NA	NA	1.00

Abbreviations: SAP, staged angioplasty; CAS, carotid artery stenting; PP, per-protocol; HPP, hyperperfusion phenomenon